Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis.
Abstract
Objectives Elevated circulating levels of interleukin 6 (IL-6) have been associated with cancer metastasis. IL-6 binds either to membrane or to soluble IL-6 receptor (IL-6sR), which then induces homodimerization of gp130 that activates downstream signaling. We tested the hypothesis that preoperative plasma IL-6 and IL-6sR levels are associated with prostate cancer stage, progression, and metastasis after radical prostatectomy.Methods Plasma levels of IL-6 and IL-6sR were measured in 120 consecutive patients who underwent radical prostatectomy for clinically localized prostate cancer, 44 healthy men without any cancer, 19 men with prostate cancer metastatic to the regional lymph nodes, and 10 men with prostate cancer metastatic to bone.Results Plasma IL-6 and IL-6sR levels were highest in patients with bone metastases (P <0.001). The preoperative IL-6 and IL-6sR levels were associated with the preoperative prostate-specific antigen (PSA) level (P </=0.041), prostatectomy tumor volume (P </=0.048), and final Gleason sum (P </=0.042). The preoperative IL-6 and IL-6sR levels and biopsy Gleason sum were independent predictors of PSA progression (P </=0.029). However, in a model that included both IL-6 and IL-6sR, only IL-6sR and the biopsy Gleason sum predicted progression (P </=0.040). In patients whose disease progressed, the preoperative IL-6 and IL-6sR levels were highest in those with presumed aggressive failure (P </=0.042).Conclusions Plasma IL-6 and IL-6sR levels were dramatically elevated in the men with prostate cancer metastatic to bone. In patients with clinically localized prostate cancer, the preoperative plasma IL-6 and IL-6sR levels independently predicted biochemical progression after surgery, presumably because of an association with occult metastatic disease present at the time of radical prostatectomy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The levels of IL-6 and its soluble receptor IL-6sR in circulating plasma are increased in patients with aggressive metastatic disease and can be predictive of recurrence after treatment of localized cancer.
“The levels of IL-6 and its soluble receptor, IL-6sR, in circulating plasma is increased in patients with aggressive metastatic disease and can be predictive of recurrence after treatment of localized cancer (17).”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [17]
Cites
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,077 · see citing works
A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer
Kattan, M. W., Eastham, J. A., Stapleton, A. M. F., Wheeler, T. M., & Scardino, P. T. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.10.766 · Cited by 1,243 · see citing works
IL-6 is produced by osteoblasts and induces bone resorption.
Ishimi, Y., Miyaura, C., Jin, C., Akatsu, T., Abe, E., Nakamura, Y. K., Yamaguchi, A., Yoshiki, S., Matsuda, T., Hirano, T., et al. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.10.3297 · Cited by 1,128 · see citing works
Soluble receptors for cytokines and growth factors: generation and biological function
Rose‐John, S., & Heinrich, P. C. (1994) · Biochemical Journal · doi:10.1042/bj3000281 · Cited by 784 · see citing works
Evidence for the involvement of interleukin 6 in experimental cancer cachexia.
Strassmann, G., Fong, M., Kenney, J. S., & Jacob, C. O. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115767 · Cited by 660 · see citing works
Prediction of Progression Following Radical Prostatectomy
Epstein, J. I., Partin, A. W., Sauvageot, J., & Walsh, P. C. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199603000-00004 · Cited by 560 · see citing works
Hobisch, A., Eder, I. E., Putz, T., Horninger, W., Bartsch, G. C., Klocker, H., & Čulig, Z. (1998) · PubMed · Cited by 437 · see citing works
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
Blay, J., Négrier, S., Combaret, V., Attali, S., Goillot, E., Merrouche, Y., Mercatello, A., Ravault, A., Tourani, J. M., & Jf, M. (1992) · PubMed · Cited by 420 · see citing works
Adler, H. L., McCURDY, M. A., Kattan, M. W., Timme, T. L., Scardino, P. T., & Thompson, T. C. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(01)62092-5 · Cited by 387 · see citing works
Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
Nakashima, J., Tachibana, M., Horiguchi, Y., Oya, M., Ohigashi, T., Asakura, H., & Murai, M. (2000) · PubMed · Cited by 351 · see citing works
Interleukin-6: A candidate mediator of human prostate cancer morbidity
Twillie, D. A., Eisenberger, M. A., Carducci, M. A., Hseih, W.-S., Kim, W. Y., & Simons, J. W. (1995) · Urology · doi:10.1016/s0090-4295(99)80034-x · Cited by 286 · see citing works
Peters, M. J., Jacobs, S., Ehlers, M., Vollmer, P., Müllberg, J., Wolf, E., Brem, G., Büschenfelde, K. H. M. Z., & Rose‐John, S. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.4.1399 · Cited by 276 · see citing works
Characterization of the role of IL‐6 in the progression of prostate cancer
Chung, T., Yu, J.-Q., Spiotto, M., Bartkowski, M., & Simons, J. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19990215)38:3 · Cited by 253 · see citing works
Longitudinal Screening for Prostate Cancer With Prostate-Specific Antigen
Smith, D. S. (1996) · JAMA · doi:10.1001/jama.1996.03540160031029 · Cited by 219 · see citing works
Shariat, S. F., Shalev, M., Menesses-Diaz, A., Kim, I. Y., Kattan, M. W., Wheeler, T. M., & Slawin, K. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2856 · Cited by 215 · see citing works
Farkas, A., Schneider, D. F., Perrotti, M., Cummings, K. B., & Ward, W. S. (1998) · Urology · doi:10.1016/s0090-4295(98)00242-8 · Cited by 201 · see citing works
Leventis, A. K., Shariat, S. F., Kattan, M. W., Butler, E. B., Wheeler, T. M., & Slawin, K. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1030 · Cited by 193 · see citing works
Decelerating growth and human breast cancer
Spratt, J. A., von Fournier, D., Spratt, J. S., & Weber, E. (1993) · Cancer · doi:10.1002/1097-0142(19930315)71:6 · Cited by 189 · see citing works
Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma
Seymour, J. F., Talpaz, M., Cabanillas, F., Wetzler, M., & Kurzrock, R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.575 · Cited by 164 · see citing works
Oka, M., Yamamoto, K., Takahashi, M., Hakozaki, M., Abe, T., Iizuka, N., Hazama, S., Hirazawa, K., Hayashi, H., Tangoku, A., et al. (1996) · PubMed · Cited by 159 · see citing works
Interleukin-6 is a prognostic factor in multiple myeloma [letter] [see comments]
Ludwig, H., Nachbaur, D., Fritz, E., Krainer, M., & Huber, H. (1991) · Blood · doi:10.1182/blood.v77.12.2794.2794 · Cited by 158 · see citing works
CYTOKINE VARIATIONS IN PATIENTS WITH HORMONE TREATED PROSTATE CANCER
Wise, G. J., Marella, V. K., Talluri, G. S., & Shirazian, D. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67289-8 · Cited by 152 · see citing works
Fresh tissue harvest for research from prostatectomy specimens
Wheeler, T. M., & Lebovitz, R. M. (1994) · The Prostate · doi:10.1002/pros.2990250507 · Cited by 139 · see citing works
Tanner, J. E., & Tosato, G. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115283 · Cited by 89 · see citing works
Soluble interleukin‐6 receptor as a prognostic factor in multiple myeloma
Pulkki, K., Pelliniemi, T., Rajamäki, A., Tienhaara, A., Laakso, M., & Lahtinen, R. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.d01-1470.x · Cited by 88 · see citing works
The definition of biochemical failure in patients treated with definitive radiotherapy
Kattan, M. W., Fearn, P., Leibel, S. A., & Potters, L. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01359-6 · Cited by 71 · see citing works
Soluble Interleukin 6 Receptor is Biologically Active In Vivo
Mackiewicz, A. A., Wiznerowicz, M., Roeb, E., Karczewska, A., Nowak, J., Heinrich, P. C., & Rose‐John, S. (1995) · Cytokine · doi:10.1006/cyto.1995.1019 · Cited by 55 · see citing works
AKIMOTO, S., Okumura, A., & Fuse, H. (1998) · Endocrine Journal · doi:10.1507/endocrj.45.183 · Cited by 55 · see citing works
Soluble Receptors for Cytokines and Growth Factors
Müller‐Newen, G., Köhne, C., & Heinrich, P. C. (2009) · International Archives of Allergy and Immunology · doi:10.1159/000237353 · Cited by 45 · see citing works
Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma
Nehls, O., Klump, B., Holzmann, K., Lammering, G., Borchard, F., Gruenagel, H. H., Gaco, V., Gregor, M., & Porschen, R. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990615)85:12 · Cited by 38 · see citing works
Shariat, S. F., Bergamaschi, F. A. M., Adler, H. L., Nguyen, C., Kattan, M. W., Wheeler, T. M., & Slawin, K. M. (2000) · Urology · doi:10.1016/s0090-4295(00)00648-8 · Cited by 36 · see citing works
Flagged first, then by citations
4 of the 35 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Interleukin-6 in Aging and Chronic Disease: A Magnificent Pathway
Maggio, M. G., Guralnik, J. M., Longo, D. L., & Ferrucci, L. (2006) · The Journals of Gerontology Series A · doi:10.1093/gerona/61.6.575 · Cited by 687 · see citing works
Human prostate cancer risk factors
Bostwick, D. G., BURKE, H. B., Djakiew, D., Euling, S. Y., Ho, S., Landolph, J. R., MORRISON, H. I., Sonawane, B. R., Shifflett, T., Waters, D. J., et al. (2004) · Cancer · doi:10.1002/cncr.20408 · Cited by 644 · see citing works
Obesity and Prostate Cancer: Weighing the Evidence
Allott, E. H., Masko, E. M., & Freedland, S. J. (2012) · European Urology · doi:10.1016/j.eururo.2012.11.013 · Cited by 601 · see citing works
“Circulating IL-6 levels are elevated in PCa patients with metastatic relative to organ-confined disease [73,74], and they are associated with time to progression to metastatic disease [75].”
BackgroundLahn, M. M. F., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 558 · see citing works
Androgen receptor signaling in prostate cancer development and progression
Tindall, D. J., & Lonergan, P. E. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.83937 · Cited by 544 · see citing works
Michalaki, V., Syrigos, K., Charles, P., & Waxman, J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601814 · Cited by 406 · see citing works
“IL-6 and TNF-a, two cytokines with multiple and overlapping biological properties, are involved in prostate cancer development (Shariat et al, 2001; Smith et al, 2001).”
Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence
Taplin, M., & Balk, S. P. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10653 · Cited by 392 · see citing works
Inflammation and prostate cancer: the role of interleukin 6 ( IL ‐6)
Nguyen, D. P., Li, J., & Tewari, A. K. (2013) · British Journal of Urology · doi:10.1111/bju.12452 · Cited by 357 · see citing works
Bone Loss following Hypogonadism in Men with Prostate Cancer Treated with GnRH Analogs
Mittan, D., Lee, S., Miller, E. P., Perez, R., Basler, J. W., & Bruder, J. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.8.8782 · Cited by 278 · see citing works
E., O. I., McGaw, L. J., Naidoo, V., & Eloff, J. N. (2007) · AFRICAN JOURNAL OF BIOTECHNOLOGY · doi:10.5897/ajb2007.000-2457 · Cited by 248 · see citing works
“Cancer Increases IL-6 and IL-6sR are associated with progression and metastasis of prostate cancer (Shariat et al., 2001).”
BackgroundEpidemiology of Inflammation and Prostate Cancer
Platz, E. A., & Marzo, A. M. D. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000108131.43160.77 · Cited by 247 · see citing works
Yuan, T., Veeramani, S., & Lin, M. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0061 · Cited by 232 · see citing works
“Results of clinical studies reveal that the serum level of interleukin-6 (IL-6) is elevated in patients with PCa, especially hormonerefractory and metastatic PCa (Adler et al. 1999, Drachenberg et al. 1999, Shariat et al. 2001).”
BackgroundKattan, M. W., Shariat, S. F., Andrews, B., Zhu, K., Canto, E. A., Matsumoto, K., Muramoto, M., Scardino, P. T., Ohori, M., Wheeler, T. M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.037 · Cited by 208 · see citing works
The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases
Kallen, K. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(02)00325-7 · Cited by 205 · see citing works
Fizazi, K. S., Bono, J. S. D., Fléchon, A., Heidenreich, A., Voog, É., Davis, N. B., Qi, M., Bandekar, R. R., VERMEULEN, J. T., Cornfeld, M. J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.014 · Cited by 197 · see citing works
Systematic review of the association between circulating interleukin-6 (IL-6) and cancer
Heikkilä, K., Ebrahim, S., & Lawlor, D. A. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.02.047 · Cited by 232 · see citing works
Tumor markers in prostate cancer I: Blood-based markers
Shariat, S. F., Semjonow, A., Lilja, H. G., Savage, C. J., Vickers, A. J., & Bjartell, A. S. (2011) · Acta Oncologica · doi:10.3109/0284186x.2010.542174 · Cited by 174 · see citing works
McCarty, M. F. (2004) · Integrative Cancer Therapies · doi:10.1177/1534735404270757 · Cited by 170 · see citing works
“Serum levels of IL-6 and of IL-6 receptors are typically elevated in patients with advanced prostate cancer, particularly bone metastases, and correlate with poor prognosis.(347,361,362) In the PC-3 and DU145 cell lines, increased activity”
BackgroundElevation of cytokine levels in cachectic patients with prostate carcinoma
Pfitzenmaier, J., Vessella, R. L., Higano, C. S., Noteboom, J. L., Wallace, D., & Corey, E. (2003) · Cancer · doi:10.1002/cncr.11178 · Cited by 167 · see citing works
“Shariat et al.(24) reported increased levels of IL-6 in patients with CaP who had bone metastases, and Wise et al.”
BackgroundShariat, S. F., Kattan, M. W., Traxel, E. J., Andrews, B., Zhu, K., Wheeler, T. M., & Slawin, K. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0768-03 · Cited by 166 · see citing works
“Remarkably, we recently demonstrated that in patients undergoing radical prostatectomy for clinically localized disease, preoperative plasma TGF- 1, IL-6, and IL-6sR were associated with eventual prostate cancer progression, when adjusted for the effects of clinical stage, biopsy Gleason sum and preoperative PSA (16,…”
BackgroundMethodResultInfluentialCytokines and Chemokines as Mediators of Prostate Cancer Metastasis
Adekoya, T. O., & Richardson, R. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124449 · Cited by 156 · see citing works
“In bone metastatic patients for example, levels of both IL-6 and soluble IL-6 receptor (IL-6-SR) has been found to be increased [188].”
BackgroundEmerging Biomarkers for the Diagnosis and Prognosis of Prostate Cancer
Sardana, G., Dowell, B. L., & Diamandis, E. P. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.110668 · Cited by 155 · see citing works
“Increased concentrations of IL-6 and its receptor have been demonstrated in metastatic and androgen-independent CaP ( 66 ) and have been suggested as candidate markers of CaP progression (67).”
BackgroundMinireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer
Lamont, K. R., & Tindall, D. J. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0469 · Cited by 150 · see citing works
“The levels of IL-6 and its soluble receptor, IL-6sR, in circulating plasma is increased in patients with aggressive metastatic disease and can be predictive of recurrence after treatment of localized cancer (17).”
BackgroundCancer-associated bone disease
Rizzoli, R., Body, J. J., Brandi, M. L., Cannata-Andía, J. B., Chappard, D., Maghraoui, A. E., Glüer, C.-C., Kendler, D., Napoli, N., Παπαϊωάννου, Α., et al. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2530-3 · Cited by 150 · see citing works
“In turn, activated osteoblasts can release large amounts of IL-6, TGF-β, PDGF-BB which are potent growth factors for the tumour cells [32-34].”
BackgroundPeriprostatic Adipose Tissue as a Modulator of Prostate Cancer Aggressiveness
Finley, D. S., Calvert, V. S., Inokuchi, J., Lau, A., Narula, N., Petricoin, E. F., Zaldivar, F. P., Santos, R. T., Tyson, D. R., & Ornstein, D. K. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.06.015 · Cited by 150 · see citing works
Jorcyk, C. L., Tawara, K., & Jorcyk, C. L. (2011) · Cancer Management and Research · doi:10.2147/cmr.s18101 · Cited by 147 · see citing works
Visceral Fat Accumulation as a Risk Factor for Prostate Cancer
HAFE, P. V., Pina, F., Pérez, A., Tavares, M., & Barros, H. (2004) · Obesity Research · doi:10.1038/oby.2004.242 · Cited by 141 · see citing works
Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting
Sung, S., & Chung, L. W. K. (2002) · Differentiation · doi:10.1046/j.1432-0436.2002.700905.x · Cited by 136 · see citing works
Wu, B. J., Yin, L., Shi, C., Li, Q., Duan, P., Huang, J.-M., Liu, C., Wang, F., Lewis, M. S., Wang, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.003 · Cited by 135 · see citing works
“IL6 has been implicated in bone metastasis (Shariat et al., 2001) and has been associated with poor clinical outcomes (Nakashima et al., 2000).”
BackgroundYoon, Y., Liang, Z., Zhang, X., Choe, M., Zhu, A., Cho, H. T., Shin, D. M., Goodman, M. M., Chen, Z., & Shim, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2263 · Cited by 133 · see citing works
Obesity, Adipokines, and Prostate Cancer in a Prospective Population-Based Study
Baillargeon, J., Platz, E. A., Rose, D. P., Pollock, B. H., Ankerst, D. P., Haffner, S. M., Higgins, B., Lokshin, A. E., Troyer, D. A., Hernández, J., et al. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0082 · Cited by 132 · see citing works
“In prostate cancer patients, elevated circulating IL-6 levels have been associated with advanced disease stage, distant metastasis, metastasis-related morbidity, and decreased overall survival (29, 33-35).”
BackgroundMcKenzie, S. P., & Kyprianou, N. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20634 · Cited by 130 · see citing works
“Furthermore, preoperative serum IL-6 measurements appear to be an effective screening tool for occult metastatic disease at the time of resection [Shariat et al., 2001] and may prove valuable in the development of adjuvant therapy protocols.”
BackgroundExercise-induced myokines and their effect on prostate cancer
Kim, J., Galvao, D. A., Newton, R. U., Gray, E. S., & Taaffe, D. R. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00476-y · Cited by 126 · see citing works
IL-6/IL-6R as a potential key signaling pathway in prostate cancer development
Azevedo, A. S. (2011) · World Journal of Clinical Oncology · doi:10.5306/wjco.v2.i12.384 · Cited by 122 · see citing works
Santer, F. R., Malinowska, K., Čulig, Z., & Cavarretta, I. T. R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0200 · Cited by 119 · see citing works
“Collectively, these data suggest that selective targeting of IL-6TS might allow to refine the currently available experimental anti-IL-6 therapies against PC. Endocrine-Related Cancer (2010) 17 241–253”
BackgroundResultMean platelet volume could be possible biomarker in early diagnosis and monitoring of gastric cancer
Kılınçalp, S., Ekız, F., Başar, Ö., Mehmet Raşit, A. Y. T. E., Çoban, Ş., Yılmaz, B., Altınbaş, A., Başar, N., Aktaş, B., Tuna, Y., et al. (2013) · Platelets · doi:10.3109/09537104.2013.783689 · Cited by 114 · see citing works
“Elevated serum concentrations of pro-inflammatory cytokines such as IL-6 were found significantly higher in individuals with gastric cancer, as well as in patients with other inflammation related cancers, such as colon and prostate cancers [28, 29].”
BackgroundExpression of STAT3 in Prostate Cancer Metastases
Don‐Doncow, N., Marginean, F. E., Coleman, I. M., Nelson, P. S., Ehrnström, R. A., Krzyzanowska, A., Morrissey, C. M., Hellsten, R., & Bjartell, A. S. (2016) · European Urology · doi:10.1016/j.eururo.2016.06.018 · Cited by 112 · see citing works
“Published by Elsevier shown that IL6 is a main driving force in pSTAT3 activation, and is highly expressed in PCa patients with poor prognostic outcome [5].”
BackgroundIL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma
Long, K. B., Tooker, G. M., Tooker, E., Luque, S. L., Lee, J. W., Pan, X., & Beatty, G. L. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0899 · Cited by 112 · see citing works
“sIL6R levels are naturally detected in the circulation (38), but are increased in patients with cancer that could lead to the formation of IL6/sIL6R complexes and subsequent IL6 trans-signaling (39, 40).”
BackgroundRoyuela, M., Ricote, M., Parsons, M. S., García‐Tuñón, I., Paniagua, R., & Miguel, M. P. D. (2003) · The Journal of Pathology · doi:10.1002/path.1476 · Cited by 110 · see citing works
Inder, K. L., Ruelcke, J. E., Petelin, L., Moon, H., Choi, E. A., Rae, J., Blumenthal, A., Hutmacher, D. W., Saunders, N. A., Stow, J. L., et al. (2014) · Journal of Extracellular Vesicles · doi:10.3402/jev.v3.23784 · Cited by 101 · see citing works
Wang, Y., Li, L., Guo, X., Jin, X., Sun, W., Zhang, X., & Xu, R. C. (2012) · Cytokine · doi:10.1016/j.cyto.2012.04.020 · Cited by 102 · see citing works
Liu, C., Zhu, Y., Lou, W., Cui, Y., Evans, C. P., & Gao, A. C. (2013) · The Prostate · doi:10.1002/pros.22741 · Cited by 101 · see citing works
Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone
Lü, Y., Chen, Q., Corey, E., Xie, W., Fan, J., Mizokami, A., & Zhang, J. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9226-7 · Cited by 101 · see citing works
SRC-3/AIB1: transcriptional coactivator in oncogenesis1
Yan, J., Tsai, S. Y., & Tsai, M. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00315.x · Cited by 99 · see citing works
Virk, M. S., & Lieberman, J. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2169 · Cited by 108 · see citing works
“IL-6 Regulates osteoblast function [88]”
Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership
Dobrovolskaia, M. A., & Kozlov, S. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009054629645 · Cited by 96 · see citing works
Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6→Androgen Receptor→TGF-β→MMP-9 Signals
Wang, X., Lee, S. O., Xia, S., Jiang, Q., Luo, J., Li, L., Yeh, S., & Chang, C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0895 · Cited by 95 · see citing works
“IL-6 has been considered as an important growth-regulatory factor in human prostate cancer (21, 24) and has roles in metastases and morbidity (25).”
BackgroundRicote, M., García‐Tuñón, I., de Bethencourt, F. R., Fraile, B., Paniagua, R., & Royuela, M. (2004) · Cancer · doi:10.1002/cncr.20142 · Cited by 94 · see citing works
Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics.
Ancrile, B. B., O'Hayer, K., & Counter, C. (2008) · Molecular Interventions · doi:10.1124/mi.8.1.6 · Cited by 96 · see citing works
Belluco, C., Olivieri, F., Bonafè, M., Giovagnetti, S., Mammano, E., Scalerta, R., Ambrosi, A., Franceschi, C., Nitti, D., & Lise, M. (2003) · PubMed · Cited by 90 · see citing works
Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens
Westdorp, H., Sköld, A. E., Snijer, B. A., Franik, S., Mulder, S. F., Major, P. P., Foley, R., Gerritsen, W. R., & de Vries, I. J. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00191 · Cited by 89 · see citing works
“IL-6 have been associated with more aggressive cancer progression and decreased survival in PCa (142).”
BackgroundSnoussi, K., Strosberg, A. D., Bouaouina, N., Ahmed, S. B., & Chouchane, L. (2005) · PubMed · Cited by 86 · see citing works
gp130: a promising drug target for cancer therapy
Xu, S., & Neamati, N. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.830105 · Cited by 82 · see citing works
“Clinically, plasma IL-6 and sIL-6R levels were significantly elevated in association with prostate cancer progression and metastasis [89].”
BackgroundAre inflammatory cytokines the common link between cancer-associated cachexia and depression?
Illman, J., Corringham, R. E., Robinson, D., Davis, H. M., Rossi, J., Cella, D. F., & Trikha, M. (2005) · PubMed · Cited by 84 · see citing works
Osteomimicry how tumor cells try to deceive the bone
Teti, A. M. (2010) · Frontiers in Bioscience-Scholar · doi:10.2741/s110 · Cited by 83 · see citing works
Xiao, W., Hodge, D. R., Wang, L., Yang, X., Zhang, X., & Farrar, W. L. (2004) · The Prostate · doi:10.1002/pros.20113 · Cited by 83 · see citing works
“Increased IL-6 has been found in both serum [6,7] and prostate cancer tissues [5,8] in patients with metastatic prostate cancer, and can accelerate the growth of the human prostate carcinoma cancer cell line LNCaP in serum free medium [9].”
BackgroundShariat, S. F., Karam, J. A., Walz, J. C., Roehrborn, C. G., Montorsi, F., Margulis, V., Fred Saad, C., Slawin, K. M., & Karakiewicz, P. I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4969 · Cited by 80 · see citing works
Chen, J., Zhang, D., Yan, W., Yang, D., & Shen, B. (2013) · BioMed Research International · doi:10.1155/2013/901578 · Cited by 82 · see citing works
“Increased serum levels of IL-6 and its receptor (IL-6R) are associated with metastatic and hormone refractory disease [19].”
BackgroundMonocyte Chemotactic Protein 1 Promotes Lung Cancer–Induced Bone Resorptive Lesions In Vivo
Cai, Z. Y., Chen, Q., Chen, J., Lü, Y., Xiao, G., Wu, Z., Zhou, Q., & Zhang, J. (2009) · Neoplasia · doi:10.1593/neo.81282 · Cited by 77 · see citing works
“These cancers include various types of cancer, such as prostate and breast cancers, which are the tumors that preferentiallymetastasize to bone [15,30,34,35,37,38].”
BackgroundShenderov, E., Boudadi, K., Fu, W., Wang, H., Sullivan, R., Jordan, A., Dowling, D., Harb, R., Schonhoft, J. D., Jendrisak, A., et al. (2021) · The Prostate · doi:10.1002/pros.24110 · Cited by 73 · see citing works
The potential role of vitamin C in empowering cancer immunotherapy
Bedhiafi, T., Inchakalody, V. P., Fernandes, Q., Mestiri, S., Billa, N., Shahab Uddin, M. S., Merhi, M., & Dermime, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112553 · Cited by 77 · see citing works
Flanagan, J., Gray, P. K., Hahn, N. M., Hayes, J., Myers, L. J., Carney, C. P., & Sweeney, C. J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq443 · Cited by 75 · see citing works
Paule, B., Terry, S., Kheuang, L., Soyeux, P., Vacherot, F., & TAILLE, A. D. L. (2007) · World Journal of Urology · doi:10.1007/s00345-007-0175-6 · Cited by 75 · see citing works
“an increased production of IL-6 are associated in the advance of bone metastases and their morbidity [4–7] as well as in resistance to chemotherapy [8].”
BackgroundIshiguro, H., Akimoto, K., Nagashima, Y., Kojima, Y., Sasaki, T., Ishiguro-Imagawa, Y., Nakaigawa, N., Ohno, S., Kubota, Y., & Uemura, H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907044106 · Cited by 74 · see citing works
“Preoperative plasma IL-6 level is related to PSA failure after radical prostatectomy (39).”
BackgroundPersistent androgen receptor addiction in castration-resistant prostate cancer
Schweizer, M. T., & Yu, E. Y. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0225-2 · Cited by 75 · see citing works
“IL-6 has also been shown to associate with advanced stage prostate cancer and survival [141–144].”
BackgroundThe Emerging Role of Obesity, Diet and Lipid Metabolism in Prostate Cancer
Ferro, M., Terracciano, D., Buonerba, C., Lucarelli, G. T., Bottero, D., Perdonà, S., Riccardo Autorino, B., Serino, A., Cantiello, F., Damiano, R., et al. (2016) · Future Oncology · doi:10.2217/fon-2016-0217 · Cited by 73 · see citing works
Longitudinal Cytokine Expression during IMRT for Prostate Cancer and Acute Treatment Toxicity
Christensen, E. N., Pintilie, M., Evans, K., Lenarduzzi, M., Ménard, C. M., Catton, C., Diamandis, E. P., & Bristow, R. G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0245 · Cited by 72 · see citing works
Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer
Bouraoui, Y., Ricote, M., García‐Tuñón, I., Rodríguez‐Berriguete, G., Touffehi, M., Rais, N. B., Fraile, B., Paniagua, R., Oueslati, R., & Royuela, M. (2008) · Cancer Detection and Prevention · doi:10.1016/j.cdp.2008.02.007 · Cited by 71 · see citing works
Hellsten, R., Lilljebjörn, L. V., Johansson, M., Leandersson, K., & Bjartell, A. S. (2019) · The Prostate · doi:10.1002/pros.23885 · Cited by 71 · see citing works
“Increased levels of GM‐CSF and IL6 are observed in metastatic prostate cancer.(30,31) Galiellalactone had limited effect on prostate cancer cell–derived IL6 and VEGF, factors involved in MDSC generation, although GM‐CSF was significantly inhibited.”
Biomarkers for Evaluation of Prostate Cancer Prognosis
Esfahani, M., Ataei, N., & Panjehpour, M. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.7.2601 · Cited by 70 · see citing works
“It is exhibited that IL-6 acts as a paracrine and autocrine growth factor for prostate cancer cells (Shariat et al., 2001).”
BackgroundShiota, M., Yokomizo, A., & Naito, S. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0232 · Cited by 70 · see citing works
“Sharifi et al. (2008) showed that the suppression of SOD2 induced the activation of AR signaling by ROS production via the following pathways.”
BackgroundInfluentialThe Present and Future of Prostate Cancer Urine Biomarkers
Rigau, M., Oliván, M., García, M., Sequeiros, T., Montes, M., Colás, E., Llauradó, M., Planas, J., de Torres, I. M., Moróte, J., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140612620 · Cited by 68 · see citing works
“IL-6 Interleukin-6 Cytokine secreted by a variety of cell types, is involved in the immune and acute-phase response Increased concentrations of IL-6 and IL-6R in metastatic and androgen-independent PCa Diagnosis and Prognostic Blood [60–62]”
BackgroundLigand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.
Lyons, L. S., Rao, S., Balkan, W., Faysal, J., Maiorino, C. A., & Burnstein, K. L. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0158 · Cited by 67 · see citing works
Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domain
Elshan, N. G. R. D., Rettig, M. B., & Jung, M. E. (2018) · Medicinal Research Reviews · doi:10.1002/med.21548 · Cited by 67 · see citing works
“Serum levels of IL‐6 are often found to be elevated in advanced PCa patients.(111,112) Upon ligand binding to the IL‐6 receptor complex, an intracellular signaling cascade is activated where the receptor‐associated JAKs phosphorylate STAT3 at Tyr‐705.”
BackgroundBlaszczyk, N., Masri, B. A., Mawji, N. R., Ueda, T., McAlinden, G., Duncan, C. P., Bruchovsky, N., Schweikert, H.-U., Schnabel, D., Jones, E. C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0974-3 · Cited by 66 · see citing works
New blood‐based biomarkers for the diagnosis, staging and prognosis of prostate cancer
Shariat, S. F., Karam, J. A., Margulis, V., & Karakiewicz, P. I. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07283.x · Cited by 64 · see citing works
Fen, W., Liu, Z., Xia, Y., Zhou, C., Shen, X., Li, X., Han, S.-G., Zheng, Y., Mao, Z., GONG, F.-R., et al. (2015) · Oncology Letters · doi:10.3892/ol.2015.3783 · Cited by 63 · see citing works
“Elevated serum concentrations of IL-6 were significantly higher in individuals with gastric, colon and prostate cancers (42,43).”
Delk, N. A., & Farach‐Carson, M. C. (2012) · Autophagy · doi:10.4161/auto.19226 · Cited by 64 · see citing works
Shariat, S. F., Walz, J. C., Roehrborn, C. G., Zlotta, A. R., Perrotte, P., Suardi, N. R., Fred Saad, C., & Karakiewicz, P. I. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4669 · Cited by 63 · see citing works
Li, Y., Hsieh, L., Tang, R., Liao, S.-K., & Yeh, K. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.01.004 · Cited by 60 · see citing works
A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
Crowley, F., Sterpi, M., Buckley, C. W., Margetich, L., Handa, S., & Dovey, Z. (2021) · Research and Reports in Urology · doi:10.2147/rru.s264722 · Cited by 58 · see citing works
Fujita, K., Shimomura, M., Uemura, M., Nakata, W., Sato, M., Nagahara, A., Nakai, Y., Takamatsu, S., Miyoshi, E., & Nonomura, N. (2014) · The Prostate · doi:10.1002/pros.22824 · Cited by 58 · see citing works
Vibrational spectroscopy of liquid biopsies for prostate cancer diagnosis
Medipally, D., Cullen, D., Untereiner, V., Sockalingum, G. D., Maguire, A., Nguyen, T. N. Q., Bryant, J., Noone, E., Bradshaw, S., Finn, M. A., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920918499 · Cited by 58 · see citing works
Kulmatycki, K. M., & Jamali, F. (2005) · PubMed · Cited by 57 · see citing works
Cardillo, M. R., & Ippoliti, F. (2006) · PubMed · Cited by 57 · see citing works
Malignancy and systemic lupus erythematosus
Bernatsky, S., Clarke, A. E., & Ramsey‐Goldman, R. (2002) · Current Rheumatology Reports · doi:10.1007/s11926-002-0045-6 · Cited by 57 · see citing works
Cellular senescence as a possible link between prostate diseases of the ageing male
Fiard, G., Stavrinides, V., Chambers, E. S., Heavey, S., Freeman, A., Ball, R., Akbar, A. N., & Emberton, M. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00496-8 · Cited by 56 · see citing works
Coutant, D. E., Kulanthaivel, P., Turner, P. K., Bell, R. L., Baldwin, J., Wijayawardana, S., Pitou, C., & Hall, S. D. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.128 · Cited by 56 · see citing works
Prostate cancer markers: An update
Pentyala, S., Whyard, T. C., Pentyala, S., Müller, J., Pfail, J. L., Parmar, S., Helguero, C. G., & Khan, S. (2016) · Biomedical Reports · doi:10.3892/br.2016.586 · Cited by 55 · see citing works
“Another study measured the plasma levels of IL-6 and IL-6 soluble receptor in 120 consecutive patients with clinically localized prostate cancer that underwent prostatectomy (44).”
Wang, L. S., Murphy, C. T., Ruth, K. J., Zaorsky, N. G., Smaldone, M. C., Sobczak, M. L., Kutikov, A., Viterbo, R., & Horwitz, E. M. (2015) · Cancer · doi:10.1002/cncr.29472 · Cited by 53 · see citing works
“Other obesity-related biological mechanisms include higher levels of insulin(31) and insulin-like growth factor 1,(33) leading to elevated circulating growth factors, decreased levels of testosterone, and higher levels of estrogen(34) as well as high inflammatory factors such as leptin(35) and interleukin 6.(36) Chang…”
BackgroundAdvanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior
Gueron, G., Siervi, A. D., & Vazquez, E. S. (2011) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2011.64 · Cited by 52 · see citing works
Shen, X., Xia, Y., Lian, L., Zhou, C., Li, X., Han, S.-G., Zheng, Y., Gong, F.-R., Tao, M., Mao, Z., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4913 · Cited by 52 · see citing works
“Elevated IL-6 is significantly higher in individuals with gastric cancer, as well as in patients with prostate cancer (17,18).”
Sharifi, N., Hurt, E. M., Thomas, S. B., & Farrar, W. L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0591 · Cited by 52 · see citing works
Zhang, P., Wei, Q., Li, X., Wang, K., Zeng, H., Bu, H., & Li, H. (2009) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2009.01.017 · Cited by 50 · see citing works
Stromal TGF-β signaling induces AR activation in prostate cancer
Yang, F., Chen, Y., Shen, T., Guo, D., Dakhova, O., Ittmann, M., Creighton, C. J., Zhang, Y., Dang, T. D., & Rowley, D. R. (2014) · Oncotarget · doi:10.18632/oncotarget.2536 · Cited by 48 · see citing works
Nadiminty, N., & Gao, A. C. (2011) · World Journal of Urology · doi:10.1007/s00345-011-0771-3 · Cited by 47 · see citing works
“soluble IL-6 receptor have been associated with CRPC progression and are predictive of recurrence after treatment of localized cancer [50, 51].”
BackgroundPlatz, E. A., & Giovannucci, E. L. (2006) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195149616.003.0059 · Cited by 46 · see citing works
Corcoran, N. M., & Costello, A. J. (2003) · British Journal of Urology · doi:10.1046/j.1464-410x.2003.04025.x · Cited by 46 · see citing works
Pinski, J., & Dorff, T. B. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.12.026 · Cited by 45 · see citing works
Platz, E. A., Marzo, A. M. D., Erlinger, T. P., Rifai, N., Visvanathan, K., Hoffman, S. C., & Helzlsouer, K. J. (2003) · The Prostate · doi:10.1002/pros.10368 · Cited by 45 · see citing works
- Authors
- Shariat, S. F., Andrews, B., Kattan, M. W., Kim, J., Wheeler, T. M., & Slawin, K. M.
- Affiliations
- Houston Methodist (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Slawin, Kevin M.
- Venue
- Urology
- Publisher
- Elsevier BV
- Published
- 2001-12
- Volume
- 58
- Issue
- 6
- Pages
- 1008-1015
- ISSN
- 0090-4295 (ISSN-L)
- OpenAlex
- W2009017218
- Cited by
- 261
- References
- 35
- Citations by year
- 2026: 6 · 2025: 1 · 2024: 4 · 2023: 7 · 2022: 6 · 2021: 17 · 2020: 5 · 2019: 5 · 2018: 10 · 2017: 9 · 2016: 9 · 2015: 19 · 2014: 10 · 2013: 12 · 2012: 8
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Urology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1p20ca058203-01)
- National Cancer Institute (CA58203)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
- Keywords
- interleukin-6, soluble IL-6 receptor, prostate cancer, bone metastasis, biochemical recurrence, radical prostatectomy, prognostic factors, Gleason score, prostate-specific antigen, tumor progression, gp130 signaling
- MeSH terms
- Adult, Aged, Analysis of Variance, Biopsy, Bone Neoplasms, Follow-Up Studies, Humans, Male, Middle Aged, Prostate, Prostatectomy, Prostatic Neoplasms, Biomarkers, Tumor, Interleukin-6, Proportional Hazards Models, Disease Progression, Receptors, Interleukin-6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
